iRhythm Technologies to Host Analyst & Investor Day on September 21, 2022
iRhythm Technologies (NASDAQ: IRTC) will host an Analyst & Investor Day on September 21, 2022, in New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iRhythm Technologies (NASDAQ: IRTC) will host an Analyst & Investor Day on September 21, 2022, in New York City. The event will begin at 9:00 a.m. ET and will be available via live webcast on the company’s investor website. A replay and additional materials will be accessible post-event.
iRhythm, a leader in digital healthcare, focuses on advancing cardiac care through wearable biosensors and cloud-based analytics, aiming to enhance arrhythmia detection and clinical management of patients.
Details
News Market Reaction – IRTC
The recorded move for IRTC in the trading session of this news was +2.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the Company will host an Analyst & Investor Day on Wednesday, September 21, 2022, in New York City.
A live webcast of the event will begin at 9:00 a.m. ET and will be accessible at that time on the investors section of the Company’s website at investors.irhythmtech.com. A replay of the webcast and related presentation materials will be made available on the Company’s website following the conclusion of the event.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.
Investor Relations Contact
Stephanie Zhadkevich
(919) 452-5430
stephanie.zhadkevich@irhythmtech.com
iRhythm Media Contact
Morgan Mathis
(310) 528-6306
irhythm@highwirepr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.